Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

AltaRex moves to conduct clinical trial with OvaRex in more advanced ovarian cancer

Nov. 6, 1998

Adoptive immunotherapy of cancer with HSPs covered by U.S. patent

Nov. 4, 1998

Ribi ImmunoChem withdraws European Melacine application; focuses on U.S. and Canada

Nov. 3, 1998

FDA okays U.S. portion of multinational study evaluating Theratope

Nov. 2, 1998

Genentech begins shipping Herceptin to U.S. oncologists

Oct. 30, 1998

Positive initial clinical findings reported for first-generation GVAX vaccine for melanoma

Oct. 29, 1998

Positive efficacy and safety results reported for IDEC-Y2B8/Rituxan in NHL

Oct. 29, 1998

Japanese patent allowed for Maxamine technology

Oct. 22, 1998

Coulter announces positive investigational phase III results from Bexxar in NHL

Oct. 22, 1998

Endorex adds second site to phase II ImmTher trial

Oct. 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.